Pharmacological treatment for right ventricular failure
This technology is a pharmacological method for preventing and treating right ventricular failure.
Unmet Need: A treatment for right ventricular failure
Right ventricular (RV) dysfunction is associated with the worst outcomes for patients with either heart failure or pulmonary hypertension. This condition is difficult to diagnose due to the nonspecific nature of the symptoms. Furthermore, there are currently no therapies to prevent or treat RV failure.
The Technology: Pharmacological method for preventing and treating right ventricular failure
This technology uses a weighted gene co-expression network to identify genes correlated with RV failure and can be used to diagnose patients at risk for cardiopulmonary disease. In vitro models of heart failure in combination with gene suppression studies offer a potential physiological explanation for RV failure, identifying therapeutic targets that specifically regulate molecular mechanisms underlying this condition. To prevent and treat RVF, this technology uses pharmacological tools, including CRISPR gene editing technology, to modulate the expression of RVF-associated genes. Additionally, by detecting and measuring expression levels of these genes, this technology allows for monitoring, prognostics and treatment of RV failure.
This technology has been validated with RNA silencing in rat cardiomyocytes.
Applications:
- Diagnostic biomarker for onset of RV failure
- Prognostic tool for individuals with RV dysfunction
- Therapeutic prevention of RV failure
- Targets for small molecule and drug screening
Advantages:
- Specific treatment for RV dysfunction
- Previously unidentified diagnostic target
- Helps prevent RV failure
- Identifies individuals at an increased risk for developing RV failure
Lead Inventor:
Patent Information:
Related Publications:
Tech Ventures Reference:
IR CU18328
Licensing Contact: Jerry Kokoshka